Literature DB >> 34583969

Precision Patient Navigation to Improve Rates of Follow-up Colonoscopy, An Individual Randomized Effectiveness Trial.

Gloria D Coronado1, Andreea M Rawlings2,3, Amanda F Petrik2, Matthew Slaughter2, Eric S Johnson2,4, Peggy A Hannon5, Allison Cole5,6, Thuy Vu5, Rajasekhara R Mummadi4.   

Abstract

BACKGROUND: Colorectal cancer screening by annual fecal immunochemical test (FIT) with follow-up on abnormal results is a cost-effective strategy to reduce colorectal cancer incidence and mortality. Unfortunately, many patients with abnormal results do not complete a follow-up colonoscopy. We tested whether navigation targeted to patients who are unlikely to complete the procedure may improve adherence and long-term outcomes.
METHODS: Study participants were patients at a large, integrated health system (Kaiser Permanente Northwest) who were ages 50 to 75 and were due for a follow-up colonoscopy after a recent abnormal FIT result. Probability of adherence to follow-up was estimated at baseline using a predictive risk model. Patients whose probability was 70% or lower were randomized to receive patient navigation or usual care, with randomization stratified by probability category (<50%, 50% < 60%, 60% < 65%, 65% ≤ 70%). We compared colonoscopy completion within 6 months between the navigation and usual care groups using Cox proportional hazards regression.
RESULTS: Participants (n = 415; 200 assigned to patient navigation, 215 to usual care) had a mean age of 62 years, 54% were female, and 87% were non-Hispanic white. By 6 months, 76% of the patient navigation group had completed a colonoscopy, compared with 65% of the usual care group (HR = 1.35; 95% confidence interval, 1.07-1.72; log-rank P value = 0.027).
CONCLUSIONS: In this randomized trial, patient navigation led to improvements in follow-up colonoscopy adherence. IMPACT: More research is needed to assess the value of precision-directed navigation programs. ©2021 The Authors; Published by the American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34583969      PMCID: PMC9273475          DOI: 10.1158/1055-9965.EPI-20-1793

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  26 in total

1.  Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests.

Authors:  Yi-Chia Lee; Jean Ching-Yuan Fann; Tsung-Hsien Chiang; Shu-Lin Chuang; Sam Li-Sheng Chen; Han-Mo Chiu; Amy Ming-Fang Yen; Sherry Yueh-Hsia Chiu; Chen-Yang Hsu; Wen-Feng Hsu; Ming-Shiang Wu; Hsiu-Hsi Chen
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-01       Impact factor: 11.382

2.  Patient navigation based on predictive modeling decreases no-show rates in cancer care.

Authors:  Sanja Percac-Lima; Patrick R Cronin; David P Ryan; Bruce A Chabner; Emily A Daly; Alexandra B Kimball
Journal:  Cancer       Date:  2015-01-13       Impact factor: 6.860

3.  Predicting Non-Adherence with Outpatient Colonoscopy Using a Novel Electronic Tool that Measures Prior Non-Adherence.

Authors:  Daniel M Blumenthal; Gaurav Singal; Shikha S Mangla; Eric A Macklin; Daniel C Chung
Journal:  J Gen Intern Med       Date:  2015-01-14       Impact factor: 5.128

4.  Graphical methods for assessing violations of the proportional hazards assumption in Cox regression.

Authors:  K R Hess
Journal:  Stat Med       Date:  1995-08-15       Impact factor: 2.373

5.  Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial.

Authors:  Beverly B Green; Melissa L Anderson; Ching-Yun Wang; Sally W Vernon; Jessica Chubak; Richard T Meenan; Sharon Fuller
Journal:  J Am Board Fam Med       Date:  2014 Nov-Dec       Impact factor: 2.657

6.  Cost-effectiveness of a patient navigation intervention to increase colonoscopy screening among low-income adults in New Hampshire.

Authors:  Ketra Rice; Krishna Sharma; Chunyu Li; Lynn Butterly; Joanne Gersten; Amy DeGroff
Journal:  Cancer       Date:  2018-12-12       Impact factor: 6.860

7.  The compliance rate for the second diagnostic evaluation after a positive fecal occult blood test: A systematic review and meta-analysis.

Authors:  Rachel Gingold-Belfer; Haim Leibovitzh; Doron Boltin; Nidal Issa; Tsachi Tsadok Perets; Ram Dickman; Yaron Niv
Journal:  United European Gastroenterol J       Date:  2019-02-06       Impact factor: 4.623

8.  Evaluation of a patient navigation program to promote colorectal cancer screening in rural Georgia, USA.

Authors:  Sally Honeycutt; Rhonda Green; Denise Ballard; April Hermstad; Alex Brueder; Regine Haardörfer; Jennifer Yam; Kimberly J Arriola
Journal:  Cancer       Date:  2013-05-29       Impact factor: 6.860

9.  Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test.

Authors:  Reinier G S Meester; Ann G Zauber; Chyke A Doubeni; Christopher D Jensen; Virginia P Quinn; Mark Helfand; Jason A Dominitz; Theodore R Levin; Douglas A Corley; Iris Lansdorp-Vogelaar
Journal:  Clin Gastroenterol Hepatol       Date:  2016-05-19       Impact factor: 11.382

10.  Assessing the implementation of a patient navigation intervention for colonoscopy screening.

Authors:  Amy DeGroff; Lindsay Gressard; Rebecca Glover-Kudon; Ketra Rice; Felicia Solomon Tharpe; Cam Escoffery; Joanne Gersten; Lynn Butterly
Journal:  BMC Health Serv Res       Date:  2019-11-06       Impact factor: 2.655

View more
  2 in total

1.  Mailed fecal testing and patient navigation versus usual care to improve rates of colorectal cancer screening and follow-up colonoscopy in rural Medicaid enrollees: a cluster-randomized controlled trial.

Authors:  Gloria D Coronado; Michael C Leo; Katrina Ramsey; Jennifer Coury; Amanda F Petrik; Mary Patzel; Erin S Kenzie; Jamie H Thompson; Erik Brodt; Raj Mummadi; Nancy Elder; Melinda M Davis
Journal:  Implement Sci Commun       Date:  2022-04-13

2.  Commencing colorectal cancer screening at age 45 years in U.S. racial groups.

Authors:  John M Carethers
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.